Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review.

ABSTRACT:

Background

IgA nephropathy is the most common primary glomerular disease worldwide and also the most frequent cause of kidney failure. Mycophenolate mofetil (MMF) is a selective immunosuppressant widely used in many autoimmune diseases. However, the benefits and risks of MMF for the treatment of IgA nephropathy remain uncertain.

Methods

A systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to assess the efficacy and safety of MMF in IgA nephropathy patients, using the statistical software Review Manager 5.1.

Results

Eight RCTs involving 357 patients were identified and included in this review. Overall, no statistical difference was found in the therapeutic effect of MMF treatment compared with other therapies. MMF had no significan

SUBMITTER: Chen Y 

PROVIDER: S-EPMC4267433 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature